BI-D1870 | p90 ribosomal S6 kinase inhibitor
NMR (Conforms)
Available Options
| Size: | Price | Quantity | |
|---|---|---|---|
| 5 mg | $90.00 | ||
| 25 mg | $325.00 |
BI-D1870 (501437-28-1) is an inhibitor of p90 ribosomal S6 kinase (RSK; IC50’s = RSK1, 31 nM; RSK2, 24 nM; RSK3, 18 nM; RSK4, 15 nM) with selectivity over other AGC kinases.1 It protected mice from experimental autoimmune encephalomyelitis suggesting a new strategy to treat multiple sclerosis.2 BI-D1870 has also been found to alter mTORC1 signaling in an RSK-independent manner.3 BI-D1870 induced apoptosis in oral squamous cell carcinoma cells4, suppressed growth and induced apoptosis in pediatric medulloblastoma cell lines as well as sensitizing these lines to Sonic hedgehog agents5, and blocked cell proliferation and protein synthesis in dual BRAF and MEK inhibitor-resistant melanoma6.
References/Citations:
1) Gopal et al. (2007), BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo; Biochem. J. 401 (Pt 1) 29
2) Takda et al. (2016), The ribosomal S6 kinase inhibitor BI-D1870 ameliorated experimental autoimmune encephalomyelitis in mice; Immunobiology 221 188
3) Roffe et al. (2015), Two widely used RSK inhibitors, BI-D1870 and SL0101, alter mTORC1 signaling in a RSK-independent manner; Cell Signal. 27 1630
4) Chiu et al. (2014), Antitumor effects of BI-D1870 on human oral squamous cell carcinoma; Cancer Chemother. Pharmacol. 73 237
5) Pambid et al. (2014), Overcoming resistance to Sonic hedgehog inhibition by targeting p90 ribosomal S6 kinase in pediatric medulloblastoma; Pediatr. Blood Cancer 61 107
6) Theodosakis et al. (2017), p90RSK Blockade Inhibits Dual BRAF and MEK Inhibitor-Resistant Melanoma by Targeting Protein Synthesis; J. Invest. Dermatol. 137 2187
NMR (Conforms)
Safety Data Sheet:
Product Data Sheet:
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
BI-D1870 (501437-28-1) is an inhibitor of p90 ribosomal S6 kinase (RSK; IC50’s = RSK1, 31 nM; RSK2, 24 nM; RSK3, 18 nM; RSK4, 15 nM) with selectivity over other AGC kinases.1 It protected mice from experimental autoimmune encephalomyelitis suggesting a new strategy to treat multiple sclerosis.2 BI-D1870 has also been found to alter mTORC1 signaling in an RSK-independent manner.3 BI-D1870 induced apoptosis in oral squamous cell carcinoma cells4, suppressed growth and induced apoptosis in pediatric medulloblastoma cell lines as well as sensitizing these lines to Sonic hedgehog agents5, and blocked cell proliferation and protein synthesis in dual BRAF and MEK inhibitor-resistant melanoma6.
References/Citations:
1) Gopal et al. (2007), BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo; Biochem. J. 401 (Pt 1) 29
2) Takda et al. (2016), The ribosomal S6 kinase inhibitor BI-D1870 ameliorated experimental autoimmune encephalomyelitis in mice; Immunobiology 221 188
3) Roffe et al. (2015), Two widely used RSK inhibitors, BI-D1870 and SL0101, alter mTORC1 signaling in a RSK-independent manner; Cell Signal. 27 1630
4) Chiu et al. (2014), Antitumor effects of BI-D1870 on human oral squamous cell carcinoma; Cancer Chemother. Pharmacol. 73 237
5) Pambid et al. (2014), Overcoming resistance to Sonic hedgehog inhibition by targeting p90 ribosomal S6 kinase in pediatric medulloblastoma; Pediatr. Blood Cancer 61 107
6) Theodosakis et al. (2017), p90RSK Blockade Inhibits Dual BRAF and MEK Inhibitor-Resistant Melanoma by Targeting Protein Synthesis; J. Invest. Dermatol. 137 2187
Related products
-
Cantharidin | Phosphatase PP2A inhibitor
From $40.00CAS:56-25-7Catalog Number:10-1013Activity:Phosphatase PP2A inhibitorChemical Name:3α,7α-Dimethylhexahydro-4,7-epoxyisobenzofuran-1,3-dioneMolecular Weight:196.2Molecular Formula:C10H12O4Solubility:Soluble in DMSO (up to 20 mg/ml) or in Ethanol (up to 5 mg/ml).Physical Properties:White solidPurity:98% by TLC
NMR (Conforms)Storage Temperature:-20°CStability:Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 2 weeks.Shipping Code:RT -
Sunitinib malate | VEGFR, PDGFR kinase inhibitor
From $60.00CAS:341031-54-7Catalog Number:10-1078Activity:VEGFR, PDGFR kinase inhibitorAlternate Names:SU-11248Chemical Name:N-[2-(Diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide malateMolecular Weight:532.57Molecular Formula:C22H27FN4O4 C4H6O5Solubility:Soluble in DMSO (up to 13 mg/ml).Physical Properties:Orange solidPurity:98% by TLC
NMR (Conforms)Storage Temperature:-20°CStability:Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.Shipping Code:RT -
ZM-447439 | Aurora B kinase inhibitor
From $52.00CAS:331771-20-1Catalog Number:10-1037Activity:Aurora B kinase inhibitorChemical Name:N-[4-[[6-Methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]benzamideMolecular Weight:513.59Molecular Formula:C29H31N5O4Solubility:Soluble in DMSO (up to 50 mg/ml) or in Ethanol (up to 25 mg/ml).Physical Properties:White solidPurity:98% by TLCStorage Temperature:RTStability:Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months.Shipping Code:RT
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
